MedTrace Logo

In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy

NCT01976780 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2017-05-11

No results posted yet for this study

Summary

This study aims to assess the degree of artemisinin resistance in adult and pediatric subjects presenting with uncomplicated falciparum malaria in Western Kenya. The study treatments will be Artemether Lumefantrine (AL) and Artesunate Mefloquine (ASMQ).

Conditions

Interventions

DRUG

Artesunate

DRUG

Artemether Lumefantrine

DRUG

Mefloquine

Sponsors & Collaborators

  • United States Army Medical Unit - Kenya

    collaborator FED

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • Global Emerging Infections Surveillance and Response System

    lead FED

Principal Investigators

  • James F Cummings, MD · GEIS

  • Ben Andagalu, MD · Kenya Medical Research Institute/Walter Reed Project

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01976780 on ClinicalTrials.gov